KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRAS(G12D)-mutant pancreatic cancer: a phase 1b/2 trial.

HRS-4642 combined with chemotherapy achieves a 63.3% objective response rate in advanced KRAS(G12D)-mutant pancreatic cancer, showing promising antitumor activity.

• Why it matters: KRAS(G12D) is the main driver in pancreatic ductal adenocarcinoma, but effective targeted therapies are limited by toxicity and poor tumor exposure, creating a critical need for better treatments.
• What they did: A phase 1b/2 trial evaluated HRS-4642, a liposomal intravenous KRAS-G12D inhibitor, with nab-paclitaxel and gemcitabine in 31 patients, assessing safety and efficacy over a median follow-up of 12.3 months.
• The result: The combination was well tolerated, with no dose-limiting toxicities, and demonstrated significant tumor responses, supporting further research into this targeted approach for this aggressive cancer.